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cells: Activation of purified phospholipase C isozymes by
G-protein ca subunits
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ABSTRACT A cDNA encoding Gi6a, the a subunit of a
heterotrimeric guani nucleotide-binding protein, was ex-
pressed in Sf9 ceUls using recombinant baculovirus. G16a in
membrane extracts of Sf9 ceUs activated phospholipase C-.81(PLC-p81) in the presence of guanosine 5'-[Vthio]triphosphate;
the system could not be activated by A13+, Mg2+, and F-. The
Gi6a in the cYtosolic fraction of Sf9 ceHs did not stimulate
PLC-l1. Concurrent expression of the G-protein Py subunit
complex increased the amount of G16a in Sf9 cell membranes.
The guanosine 5'-['thioJtriphosphate-activated form of G16a
was purifled from cholate extracts of membranes from cells
expressing G16., and the G-protein P2 and "Y subunits. G16a
activated PLC-p1, PLC-p2, and PLC-83 in a manner essen-
tially i uishable from that of Gqa. Gl,-mediated acti-
vation of PLC-p1 and PLC-.83 greatly exceeded that of PLC-
P2. G16a did not activate PLC-V1 or PLC-81. Thus, two
distantly related members of the Gqa family, Gqa and G16a,
have the same ability to activate the known isoforms ofPLC-P.
The a subunits of heterotrimeric, signal-transducing guanine
nucleotide-binding proteins (G proteins) can be classified into
four major groups, based on amino acid sequence relation-
ships and some major functional characteristics (1). The
so-called Gqa class has four members-Gqa, Gla, G14a, and
G15a/Gl6a (2-5). Within this group, Gqa, Glla, and G14a are
very similar to one another. Gl5a and Gl6a, which are now
thought to be mouse and human homologs, are more distantly
related to Gqa (58% and 57% amino acid identity, respective-
ly); they are 85% identical to each other. All members of the
Gqa class lack the cysteine residue near the carboxyl terminus
that is the site of pertussis toxin-catalyzed ADP-ribosylation
of members of the Gi class of a subunits. Thus, Gqa proteins
are presumed to function in signaling pathways that are
immune to disruption by the toxin.
Many hormones, neurotransmitters, and growth factors
activate certain isozymes of phospholipase C (PLC) and thus
stimulate the hydrolysis of the membrane lipid phosphatidyl-
inositol 4,5-bisphosphate to yield two intracellular second
messengers, inositol 1,4,5-trisphosphate (InsP3) and diacyl-
glycerol (6). PLCs of the y subtype are in general activated
by receptors with intrinsic tyrosine kinase activity, whereas
PLCs of the P subtype are regulated by G proteins (7).
Mixtures ofGqa and Glla isolated from bovine brain or bovine
liver were first shown to activate PLC-f31 upon combination
of the purified proteins (8, 9). We have further demonstrated
that a mixture of brain Gqa/G1ia and recombinant Gqa (rGqa)
and rGii., purified individually after baculovirus-directed
expression in Sf9 insect cells, can activate purified PLC-,Bl,
PLC-,82, and PLC-/f3, but not PLC-yl or PLC-81 (10, 11).
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
A cDNA that encodes Gl6a was cloned from a human
promyelocytic leukemia (HL-60) cell library (5). In contrast
to Gqa and Gll., which are expressed ubiquitously, Gl6a is
synthesized predominantly in hematopoietic cells. We have
purified the guanosine 5'-[y-thio]triphosphate (GTP[yS])-
activated form of G16a after expression in Sf9 cells and
characterized its interactions with various isozymes of PLC.
MATERIALS AND METHODS
Construction of Recombinant Baculovirus and Sf9 Cell
Culture. A 1.25-kb DNA fragment containing the complete
coding sequence for Gl6a was excised from pKSG16 (5) by
digestion with Bal I and Xba I and was subcloned into the
Sma I and Xba I sites of the baculovirus transfer vector
pVL1393. The resulting plasmid and linearized AcRP-lacZ
viral DNA were transfected into Sf9 cells by lipofection.
Recombinant virus was plaque-purified as described (12).
Positive viral clones were identified by their capacity to
direct the expression of G16a protein in Sf9 cells, which was
detected by immunoblotting with anti-G16. antiserum B861.
Sf9 cells were grown in suspension as described (11).
Measurement of PLC Activity. PLC activity was estimated
as described (8, 11). In most cases PLC activity is expressed
as pmol of InsP3 per min per ng of PLC. To quantify
purification of G16a (Table 1), PLC specific activity is ex-
pressed as nmol of InsP3 per min per mg of protein sample
containing G16a. The amount of PLC used per assay was 2.9
ng for bovine brain PLC-13l, 1 ng for recombinant PLC-.31, 8
ng for recombinant PLC-/2, 0.2 ng for bovine brain PLC-,f3,
2 ng for PLC-yl, and 2 ng for PLC-61. Assays were per-
formed for 5 min with PLC-f81 and for 10 min with the other
phospholipases.
Purification of G16. from Sf9 Cells. Sf9 cells (8-liter culture;
1.5 x 106 cells per ml) were infected with recombinant
baculoviruses (2-5 plaque-forming units per cell) encoding
G16a and G-protein (2 and 72 subunits (13). Cells were
harvested after 48 hr by centrifugation at 1000 x g for 10 min
and were suspended in 800 ml of ice-cold lysis buffer [50mM
NaHepes, pH 7.2/1 mM EDTA/3 mM EGTA/5 mM
MgCl2/3 mM dithiothreitol/50 mM NaCl with the protease
inhibitors [phenylmethanesulfonyl fluoride, 20 pg/ml; 7-ami-
no-l-chloro-3-tosylamido-2-heptanone ("tosyllysine chloro-
methyl ketone"), 20 pg/ml; L-1-tosylamido-2-phenylethyl
chloromethyl ketone, 30 pg/ml; and lima bean trypsin inhib-
itor, 30 pug/ml]. Cells were lysed by nitrogen cavitation (Parr
bomb) at 500 psi (1 psi = 6.89 kPa) for 30 min at 4°C. Cell
lysates were centrifuged at 750 x g for 10 min to remove
intact cells and nuclei, and the supematant was further
Abbreviations: AMF, AP3+/Mg2+/F-; GTP[yS], guanosine 5'-['
thio]triphosphate; InsP3, inositol 1,4,5-trisphosphate; PLC, phos-
pholipase C; r (prefix), recombinant.
§To whom reprint requests should be addressed.
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Table 1. Purification of rG16a
PLC Specific
Volume, Protein, activity*, activity,
Step ml mg units units/mg
Cholate extract 700 1470 5700 3.8
Q-Sepharose 160 121 1200 10
Phenyl-Sepharose 110 4.5 ND
Mono-Q
(octyl glucoside) 20 0.44 520 1200
Mono-Q
(sodium cholate) 1 0.018 90 5000
ND, not done.
*One unit = 1 nmol of InsP3 per minute per 2.9 ng of PLC-,81.
centrifuged at 100,000 x g for 40 min. Membrane pellets were
suspended in 400 ml of lysis buffer with a Potter-Elvehjem
homogenizer (10 strokes). The resulting suspension (about 5
mg of protein per ml) was frozen in liquid nitrogen and stored
at -800C.
For purification of Gl6a, membranes were thawed at 30°C.
GTP[yS] was added (5 ,AM) and membranes were incubated
with the nucleotide for 30 min at 30°C; all subsequent
procedures were performed at 4°C. Membranes were ex-
tracted by addition of sodium cholate (1%, wt/vol) and
stirring for 1 hr. This mixture was then centrifuged at 100,000
x g for 40 min, and the supernatant (membrane extract) was
collected.
The membrane extract was applied to a 100-ml Q-Sepha-
rose anion-exchange column (Pharmacia) which had been
equilibrated with buffer A (50 mM NaHepes, pH 7.2/1 mM
EDTA/3 mM EGTA/5 mM MgCl2/3 mM dithiothreitol/l
,uM GTP[yS]) containing 1% sodium cholate and 50 mM
NaCl. The column was washed with 150 ml of the equilibra-
tion buffer, followed with a 500-ml linear gradient of NaCl
(50-600 mM) in bufferA plus 1% sodium cholate. The column
eluate (7-ml fractions) was assayed for capacity to activate
bovine brain PLC-p1 and by immunoblotting using antiserum
B861. Peak fractions (120 ml) were pooled and diluted 4-fold
with buffer B [buffer A containing 35% (vol/vol) glycerol]
containing 1.25 M (NH4)2SO4. Any precipitate that formed at
this stage was removed by centrifugation at 100,000 x g for
30 min. The supernatant was applied to a 30-ml column of
phenyl-Sepharose CL-4B (Pharmacia), which had been equil-
ibrated with buffer B containing 1 M (NH4)2SO4 and 0.3%
sodium cholate. The column was washed with 50 ml of
equilibration buffer, followed with a 120-ml gradient contain-
ing linearly decreasing concentrations of (NH4)2SO4 (1 M to
0) and linearly increasing concentrations of sodium cholate
(0.3-1.5%) in buffer B. The column was finally washed with
120 ml of buffer B containing 1.5% sodium cholate. Fractions
(3 ml) were collected into tubes containing 3 ul of 10 mM
GTP[yS]. G16a (immunoreactivity) was eluted broadly at the
end of the gradient and during the final column wash. We
could not assay the PLC-stimulating activity of G16a in these
fractions because of the inhibitory effect of (NH4)2SO4.
Fractions representing the peak of immunoreactivity were
pooled and concentrated to 20 ml by ultrafiltration using an
Amicon PM30 membrane. To change the detergent from
sodium cholate to octyl glucoside, the sample was twice
diluted 5-fold with bufferA containing 1% octyl glucoside and
concentrated to 20 ml. The resulting sample was applied to a
Mono-Q HR 5/5 anion-exchange column for FPLC (Phar-
macia) that had been equilibrated with buffer A containing
1% octyl glucoside. The column was washed with 5 ml of
equilibration buffer, followed by 40 ml of the same buffer
containing a linear gradient ofNaCl (0-500 mM). Most of the
G16, activity was detected in the flowthrough and wash.
These fractions (20 ml) were collected, diluted 10-fold with
buffer A containing 1% sodium cholate, and concentrated to
20 ml. The sample was then applied to a Mono-Q HR5/5
column equilibrated with buffer A containing 1% sodium
cholate and 50 mM NaCl. The column was washed with 5 ml
of equilibration buffer and a 30-mi gradient of NaCl (50-600
mM) in buffer A containing 1% sodium cholate. G16a was
eluted between 150 and 250 mM NaCl. Analysis of fractions
by silver staining of SDS/polyacrylamide gels indicated that
the fractions collected at the latter part of this peak were
essentially pure G16a. These fractions were pooled and frozen
at -800C.
Antisera. Anti-Gl6a antiserum B861 was made in rabbits
against the synthetic 11-amino acid peptide corresponding to
the carboxyl-terminal sequence of G16,. Antiserum W082
was raised in rabbits against a 19-amino acid peptide corre-
sponding to an internal sequence of Gqa (amino acids 115-
133) (14). Antiserum Z811 was raised in rabbits against a
15-amino acid peptide representing the carboxyl-terminal
sequence shared by Gq, and Gil, (11, 14).
Miscellaneous Procedures. SDS/polyacrylamide gel elec-
trophoresis ofproteins was performed according to Laemmli
(15). Protein concentrations were determined by staining
with amido black, using bovine serum albumin as a standard
(16). Immunoblotting was done with an ECL chemilumines-
cence system (Amersham) for detection. rGqa (Sf9 cell-
derived) and the Gqa-like protein(s) endogenous to Sf9 cells
were purified as described (11). rPLC-31 and rPLC-.32 were
purified from HeLa cells (17). PLC-p1, PLC-yl, and PLC-81
were purified from bovine brain, while PLC-(33 was purified
from rat brain (10, 18, 19). The following reagents were kindly
provided by colleagues at the University of Texas South-
western Medical Center: recombinant baculoviruses encod-
ing G-protein P2 and n) subunits by Jorge Ifiiguez-Lluhi;
bovine brain f8y by Jorge lfiiguez-Lluhi and Maurine Linder.
RESULTS
Recombinant G16. in Sf9 Cels. We previously reported that
active rGqa and rG1l< could be synthesized in Sf9 cells and
purified to homogeneity (11). Using the same methods, we
attempted to purify rGl6,, another member of the Gqa family.
A recombinant baculovirus encoding G16c was plaque-
purified by monitoring immunoreactivity (Western blot) in
Sf9 cells corresponding to a 44-kDa protein with antiserum
B861 (Fig. 1). The immunoreactive band was not detected in
uninfected cells or after reaction of the antiserum with the
peptide used as immunogen.
Sf9 cells were infected with baculovirus encoding Gl6a,
and membrane and cytosolic fractions were prepared after 48
hr. As shown in Fig. 1A (right two lanes), rGl6a was detected
in both the particulate and soluble fractions in roughly equal
amounts. When rGl6a was expressed together with G-protein
(32 and -Y2 subunits, most of the rGl6a immunoreactivity was
found in membranes.
We next examined the capacity of rGl6a to activate PLC-
,81. A sodium cholate extract of Sf9 cell membranes was
assayed with PLC-,81 in the presence either ofGTP[yS] or of
AMF plus GDP. When GTP[yS] was the ligand, the extract
containing rGl6, activated PLC-,B1 to an extent similar to that
observed with a cholate extract of membranes from cells
expressing rGqa (Fig. 1B). However, such activity was not
detected when the assay was performed withAMF and GDP.
In contrast, rGqa activated PLC-f31 under either condition. Of
interest, rG16a in the cytosolic fraction was inactive under
both conditions. Unlike rGqa, and rGlla, rG16a in cholate
extracts of Sf9 cell membranes did not aggregate, even when
expressed without G-protein (3 or y subunits (data not
shown).
Unfortunately, the G16o in detergent extracts of Sf9 cell
membranes was unstable unless GTP[yS] was present. When
rGi6a was extracted in the presence of AMF plus 200 ,uM
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FIG. 1. Cellular location and activity of recombinant G16a in Sf9
cells. Sf9 cells (50-ml culture) were infected with recombinant
baculoviruses encoding /galactosidase (lacZ gene product), P2, and
nY2; G16., P2, and n2; Gqa, 32, and n; or Gl6a. Membrane and cytosolic
fractions were prepared as described under Materials and Methods.
(A) Membrane (M) and cytosolic (C) fractions (10 ,ug of each) of
lacZP2y2-, GM6aY2Y, and G16.-expressing cells were subjected to
SDS/polyacrylamide gel electrophoresis and analyzed by immuno-
blotting using anti-G16s antiserum B861. Arrow indicates position of
rG16a. (B) Membranes from cells expressing lacZp2W, G16&,P2y2, and
Gqaf322 were extracted (Xt) with 1% sodium cholate in the presence
of30 ,uM A13+/5mM Mg2+/10mM F- (AMF) plus 200 AM GDP. The
cytosolic fraction (cyto) from G16a-expressing cells was similarly
supplemented with sodium cholate, AMF, and GDP. Each fraction
(5 /4) was assayed for capacity to stimulate bovine brain PLC-,13 (2.9
ng) in the presence ofeither 120 ,uM GTP['yS] (open bar) orAMF plus
200 ,IM GDP (filled bar). The fractions that were assayed with
GTP[yS] were incubated with 1 mM GTP[-yS] at 30°C for 30 min prior
to assay.
GDP and held at 4°C, the capacity of the extract to activate
PLC-,31 was lost after 24 hr (Fig. 2A). The activity of rGqa
was stable under the same conditions. In contrast, when we
extracted rGi6a in the presence of 5 ,uM GTP[yS] and held the
extract at 4°C for 24 hr, G16, activity was undiminished (Fig.
2B); the activity of rG16a was stable for at least 5 days under
this condition. We attempted to stabilize nonactivated rG16a
in several ways, including addition of high concentrations of
GDP (to 1 mM) and various concentrations of Mg2+ (to 50
mM). None was successful. We thus chose to purify
GTP[yS]-activated G16a; the nucleotide was included in all
buffers utilized for protein extraction and purification.
Purification of rG16. from Sf9 Cells. We purified rG16a from
a membrane extract of 1.2 x 1010 Sf9 cells (8-liter culture)
expressing G16aP2y2 as described under Materials and Meth-
ods. Fig. 3A shows a silver-stained preparation of purified
G16a after SDS/polyacrylamide gel electrophoresis. The
yield of rG16a was 18 jg (Table 1).
The specificity of various antisera for G16a, Sf9 cell Gqa-
like protein(s), and Gqa is shown in Fig. 3B. Antiserum B861
recognizes rG16a specifically and does not react with rGqa or
Sf9 cell Gqa. Antiserum Z811 was raised against a 15-amino
acid peptide representing the carboxyl-terminal sequence
lacZ a16 aq lacZ a16
FIG. 2. Ability of AMF and GTP[yS] to stabilize recombinant
G16a. (A) Membranes from cells expressing lacZI32'2 (lacZ), G,6iA2I(a16), and Gqlp2V2 (aq) were extracted with 1% sodium cholate in the
presence of AMF plus 200 AM GDP. These extracts (5 /4) were
assayed for their capacity to stimulate bovine brain PLC-,B1 (2.9 ng)
immediately after extraction (open bars) or after 24 hr at 4°C (filled
bars). The extracts were incubated with 1 mM GTP[yS] at 30°C for
30 min prior to assay. The final concentration ofGTP['yS] in the assay
was 120 ,uM. (B) Membranes from cells expressing lacZf32y2 (lacZ)
and G16.182W (a16) were extracted with 1% sodium cholate in the
presence of 5 ,uM GTP[yS]. These fractions (5 /4) were assayed for
their capacity to stimulate bovine brain PLC-,B1 (2.9 ng) immediately
after extraction (open bars) or after 24 hr at 4°C (filled bars). The final
concentration of GTP[yS] in the assay was 120 ,uM.
common to Gqa and Glla. Gi6a has six identical amino acid
residues within this peptide. Sf9 cell Gqa reacts with antise-
rum Z811, and rG16a reacts weakly. rG16a is not recognized
by the Gqa-specific antiserum W082.
Interactions ofPurified rG16. withPLC Isozymes. Both rGqa
and rGlia stimulate all three isozymes of PLC-,8 (11). For
comparison, rG16a and rGqa were reconstituted with rPLC-
(31, rPLC-,82, and rat brain PLC-,B3. rG16a stimulated all three
isozymes (Fig. 4), and the concentration-response curves for
activation of PLC-p1 and PLC-f32 by rG16a and rGqa are
superimposable. rG16a appeared to be slightly less effective
than rGqa with PLC-P3. Similar to the situation described
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FIG. 3. SDS/polyacrylamide gel electrophoresis and immuno-
blot analysis of purified G16., Gqa, and endogenous Sf9 cell Gqa-like
protein(s). Purified rG16a, Sf9 cell Gqa, and rGqa (50 ng of each) were
subjected to SDS/11% polyacrylamide gel electrophoresis. (A) Silver
stain of the gel. Lane 1, G16a; lane 2, Sf9 Gqa; lane 3, Gqa. Scale at
left shows the origin (Ori), positions ofmolecular weight markers (Mr
x 10-3), and the dye front (df). (B) Immunoblots of G16. (lanes 1, 4,
and 7), Sf9 cell Gqa (lanes 2, 5, and 8), and Gqa (lanes 3, 6, and 9) with
antisera B861 (lanes 1, 2, and 3), Z811 (lanes 4, 5, and 6), and W082
(lanes 7, 8, and 9). rGqa is expressed as a doublet because of
unexpectedly efficient reading of the altered polyhedron initiator
codon upstream of the inserted Gqa sequence in pVL1393 (11).
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FIG. 4. Activation of PLC-13 isoforms by rGl6a and rGqa. rG16a
(o) and rGqa (a) were reconstituted with rPLC-Bl (1 ng) (Top),
rPLC-(32 (8 ng) (Middle), or rat brain (b) PLC-,33 (0.2 ng) (Bottom).
Reaction mixtures were incubated at 30°C for 5 min (PLC-fl) or 10
min (PLC-,82 and PLC-,83). Gqa was activated with 1 mM GTP[YS]
for 1 hr at 30°C prior to assay. GTP[FyS] was present in all assays at
a final concentration of 120 pM.
previously with rGqa and rGu1a, rGl6a activated PLC-fl and
PLC-833 to a much greater extent than was observed for
PLC-,B2. Under the assay conditions employed, the half-
maximal concentrations of rGl6a required for activation of
rPLC-81l, rPLC-(32, and PLC-/83 all appeared to be about 1
nM.
Several laboratories have demonstrated that the G-protein
Pfy subunit complex can stimulate PLC-p isozyme activity
(10, 11, 20-22). rGl6a did not change the sensitivity of
PLC-(32 to stimulation by fry (Fig. 5); similar results were
obtained with rGqa and rGu1a (11).
rG16a was also reconstituted with PLC-yl and PLC-81.
rGi6a did not stimulate either of these phospholipases under
the same conditions that were effective for PLC-,B (Table 2).
Both PLC-'yl and PLC-81 were stimulated by high concen-
trations of Ca2+. Similarly, rGl6a did not stimulate adenylyl-
cyclase activity nor inhibit Gsa-stimulated adenylylcyclase
activity in S49 cyc- cell membranes (data not shown).
DISCUSSION
G16a protein was purified from a detergent extract of Sf9 cell
membranes after infection of these cells with recombinant
baculoviruses encoding G16, and G-protein (32 and y2 sub-
units. In contrast to the situation encountered with recom-
binant Gqa (11), G16a did not aggregate, even when it was
10 100 1000
[183], nM
FIG. 5. Effect of G16, and Gqa on activation of PLC-,82 by the
G-protein )9'y subunit complex. Activation of rPLC-,82 (8 ng) by
bovine brain f8y was determined either in the absence (A) or in the
presence of 10 nM G16, (0) or 10 nM Gqa (o). Gqc was activated with
1 mM GTP[yS] for 1 hr at 30°C prior to assay. GTP('yS] was present
in all assays at a final concentration of 120 AM.
expressed without (3 and 'y subunits. After extraction, mem-
brane-bound recombinant G16. was able to stimulate PLC-
,B1, whereas cytosolic Gl6a was inactive. Thus, we expressed
Gl6a along with (2 and 'y2 to increase the amount of Gl6a in
the membrane extract. Nevertheless, the yield was modest
and only 18 Mg of recombinant G16a was purified from an
8-liter culture of Sf9 cells.
We do not understand the difference between the cytosolic
and membrane-bound forms of rGl6,. The cytosolic protein,
unassociated with Bry, may denature quickly, perhaps be-
cause of rapid dissociation of GDP. Alternatively, cytosolic
G16a may lack some posttranslational modification necessary
for activation of PLC-P. Concurrent expression of Py could
be necessary for such modification, perhaps by facilitating
translocation of G16a to the membrane. The a subunits of
most G proteins are now known to be palmitoylated (23).
When expressed in Sf9 cells, membrane-bound forms of Gsa,
Go., and G,a are palmitoylated, but the cytosolic forms of
these proteins are not. Membrane-bound G16 is also labeled
when Sf9 cells are incubated with [3H]palmitate. It will be
interesting to assess the effect of palmitoylation on the
functions of G16a and other G-protein a subunits.
We were not able to activate Gi6a with AMF; this is unique
among G-protein a subunits. Similarly, the combination of
AMF and GDP failed to stabilize G16a in detergent extracts of
Sf9 cell membranes. AMF is thought to bind to the GDP-
liganded form of G-protein a subunits, activating these pro-
teins by mimicking the fy phosphate ofGTP (24). The lack of
effect of AMF on Gi6a suggests that there may be a critical
difference in the guanine nucleotide-binding domain of this
protein. A highly conserved sequence, Gly-Ala-Gly-Glu-Ser-
Gly-Lys-Ser, is found in the amino-terminal portion of the
guanine nucleotide-binding domain of most G-protein a sub-
Table 2. Effect of rG16, and rGqa on PLC-'yl and PLC-81
Activity,
pmol/(min-ng)
Addition PLC-yl PLC-81
None 9.9 2.2
30 nM G16a 9.2 1.6
30nMGqa 9.0 3.1
30 nM Ca2+ (free) 4.2 2.3
100 ,uM Ca2+ (free) 12.3 53.3
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units. The alanine residue in this sequence is replaced by
threonine in members of the Gqa family other than G15a/Gl6a,
and Ala-Gly-Glu is replaced by Thr-Ser-Asn in Gza. The
guanine nucleotide-binding properties of Gqa, Glla, and Gza
are known to differ substantially from those of other G-pro-
tein a subunits (11, 25). Perhaps the more drastic substitution
of proline for alanine in Gl6a is responsible for loss of
activation of the protein by AMF. Purification of the nonac-
tivated form of Gl6a will be necessary to characterize the
guanine nucleotide-binding properties of the protein.
rGl6a activated all three isoforms of PLC-,B when the
purified proteins were reconstituted. Gl6o was not able to
activate PLC-yl, PLC-81, or adenylylcyclase. These data are
generally consistent with previous experiments, wherein
purified PLC isozymes were added to membranes from COS
cells overexpressing Gl6a (26, 27). However, we were unable
to detect substantial differences between concentrations of
G16a and Gqa necessary to activate the PLC isoforms. Lee et
al. (26) reported that Gl6a was a more potent activator of
PLC-,32 than was Gqa or Glla. This difference may be due to
differences in assay conditions or to the method used to
quantitate the amount of Ga protein.
There are many examples wherein different G-protein a
subunits activate the same effector, including the capacity of
Gqa, Gila, and G16a, to activate PLC-31, PLC-,82, and
PLC-,83. The situation with G16, appears unique, however, in
that its amino acid sequence is substantially divergent from
other members of the Gqa family. Of interest, Gl5a and Gl6a
are now believed to represent mouse and human homologs of
the same gene product (4), indicating that the sequence of this
protein is much more variable among species than are the
sequences of other G-protein a subunits. Perhaps there are
other, unknown effectors that are regulated differentially by
Gqa, for example, and Gl6a. Gqa and G16a may also interact
with different sets of receptors. This possibility is probably
enhanced by the fact that the distribution of G16, is very
restricted when compared with that of other members of the
Gqc family.
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